Here are the contact details, also some other research that is happening around the world.

Professor Wei Zuo and Team (Tongji University and Regend Therapeutics Ltd.)
• Institution: Tongji University, Shanghai, China and Regend Therapeutics Ltd.
• Research Focus: Autologous P63+ lung progenitor cell therapy to regenerate damaged lung tissue in COPD patients.

Other research:

• Stem Cell Research: Various groups are exploring stem cells, which can differentiate into any cell type, for lung repair. However, results have been inconsistent compared to progenitor cells, which are more specific to lung tissue (Labiotech.eu).

• Hyaluronan Therapy: A pilot study led by Drs. Stavros Garantziotis (NIH) and Raffaele Incalzi (Campus Bio-Medico University, Italy) found that inhaled hyaluronan, a naturally occurring sugar, improved lung function in hospitalized COPD patients by reducing inflammation and aiding tissue repair (NIH News).

• Precision Medicine: Researchers are investigating COPD subtypes based on inflammatory profiles to develop targeted therapies. This work is still in early stages but could lead to personalized treatments (Time Magazine).

Institutions and Organizations
• National Heart, Lung, and Blood Institute (NHLBI): Supports COPD research and developed the COPD National Action Plan to improve diagnosis, prevention, and treatment (NHLBI).
• Royal Brompton & Harefield Hospitals (UK): Conducting trials on novel treatments, such as vagus nerve ablation to reduce airway obstruction (RBHT).